Brief: Oryzon Genomics Q1 Income From Operations USD -6.666 Million
14/05/2026 15:48
May 14 (Reuters) - Oryzon Genomics Q1 operating expenses USD 6.666 million. Q1 net income USD -1.993 million
Recent news on ORYZON Genomics SA
See all newsBrief: Oryzon Gets New Patent Grants For Vafidemstat In Four Countries
Brief: Oryzon Gets EMA Approval To Start Phase II Study Of Vafidemstat For PMS Treatment
Spanish stocks - Factors to watch on Aug 31
Brief: Oryzon Gets U.S. Patent Allowance For Iadademstat And Gilteritinib Drug Combo Application
Spanish stocks - Factors to watch on July 28